Adu-CAN-umab? Reading The Tea Leaves For Biogen’s US Filing For Alzheimer’s Drug

 
• By Michael McCaughan
Priority Stamp
The US FDA has made clear the review of Biogen's aducanumab application is a priority, but is it approvable? • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers